MRRS adds "Asthma Therapeutics in Asia-Pacific Markets to 2021 – High Prevalence and Launch of Late-Stage Biologics will Drive the Market in Spite of Affordability Concerns" latest studies, published in November 2016. It is a professional and in-depth study.

Summary
Asthma is a common chronic inflammatory disease of the airways, characterized by recurrent attacks of breathlessness and wheezing, which vary in frequency and severity from patient to patient. The exact causes of asthma are currently unknown, and may be the result of a combination of factors, although two major factors thought to be involved are environmental exposure and host factors, particularly genes.

Asthma treatment can be classed as either a long-term control medication, aimed at controlling persistent asthma, or a quick-relief medication, for the relief of exacerbations and acute symptoms. Long-term control medication includes Inhaled Corticosteroids (ICS), immunomodulators, leukotriene modifiers, cromolyn sodium, nedocromil and methylxanthines. In addition, Long-Acting Beta-Adrenoceptor Agonists (LABAs) can be used in combination with ICSs – but not as monotherapies – for moderate or severe persistent asthma. Currently, only one biologic – Xolair (omalizumab) – is approved as an add-on therapy for the treatment of allergic asthma in the Asia-Pacific region. Nevertheless, significant unmet need remains for the treatment of severe eosinophilic asthma.

Table of Contents
3 Marketed Products 30
3.1 Overview 30
3.2 ICS for the Maintenance Treatment of Asthma 30
3.2.1 Arnuity (fluticasone furoate) 30
3.3 ICS/LABA Combination Therapy for the Maintenance Treatment of Asthma 31
3.3.1 Seretide/Adoair (fluticasone propionate and salmeterol xinafoate) - GlaxoSmithKline 31
3.3.2 Symbicort (budesonide and formoterol fumarate) - AstraZeneca, Co-Promotion with Astellas Pharma 32
3.3.3 Relvar/Breo (vilanterol trifenatate and fluticasone furoate) - GlaxoSmithKline 33
3.3.4 Flutiform (fluticasone propionate and formoterol fumarate) - SkyePharma 34
3.4 Add-on Therapy to ICS or ICS/LABA Therapies for the Maintenance Treatment of Asthma 35
3.4.1 Xolair (omalizumab) - Novartis and Genentech 35
3.4.2 Montelukast sodium 36
3.4.3 Spiriva (tiotropium bromide) - Boehringer Ingelheim 37
3.5 Comparative Efficacy and Safety of Marketed Products 38
4 Pipeline Analysis 41
4.1 Overview 41
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 41
4.3 Pipeline by Molecular Target 43
4.4 Promising Pipeline Molecules 47
4.4.1 Mepolizumab - GlaxoSmithKline 47
4.4.2 Reslizumab - Teva Pharmaceutical 49
4.4.3 Lebrikizumab - Roche/Genentech 51
4.4.4 Dupilumab - Regeneron Pharmaceuticals in Collaboration with Sanofi 52
4.4.5 Tralokinumab - AstraZeneca 55
4.4.6 Benralizumab - AstraZeneca 56
4.5 Comparative Efficacy and Safety of Pipeline Products 58
5 Clinical Trial Analysis 62......

List of Tables and Figures 
Table 1: Asthma Therapeutics Market, Global, Classification of Asthma Severity According to GINA Guidelines (2002) 12
Table 2: Asthma Therapeutics, Global, Management of Chronic Asthma in Adults and Children above Five Years 14
Table 3: Asthma Diagnosis, Global, Symptoms and Management of Acute Asthma 15
Table 4: Asthma Trials, Global, Clinical Trial Endpoints 16
Table 5: Asthma Therapeutics, Global, All Pipeline Products, Discovery, 2015 106
Table 6: Asthma Therapeutics, Global, All Pipeline Products, Preclinical, 2015 107
Table 7: Asthma Therapeutics, Global, All Pipeline Products, Phase I, 2015 112
Table 8: Asthma Therapeutics, Global, All Pipeline Products, Phase II, 2015 113
Table 9: Asthma Therapeutics, Global, All Pipeline Products, Phase III, 2015 115
Table 10: Asthma Therapeutics, Global, All Pipeline Products, Pre-registration Phase, 2015 116
Table 11: Asthma Therapeutics Market, Asia-Pacific, Market Forecast, 2014-2021 116
Table 12: Asthma Therapeutics Market, China, Market Forecast, 2014-2021 117
Table 13: Asthma Therapeutics Market, India, Market Forecast, 2014-2021 117
Table 14: Asthma Therapeutics Market, Australia, Market Forecast, 2014-2021 118
Table 15: Asthma Therapeutics Market, South Korea, Market Forecast, 2014-2021 118
Table 16: Asthma Therapeutics Market, Japan, Market Forecast, 2014-2021 119.....

Browse Complete Report with TOC @
http://www.marketresearchreportstore.com/shop/asthma-therapeutics-in-asia-pacific-markets-to-2021-high-prevalence-and-launch-of-late-stage-biologics-will-drive-the-market-in-spite-of-affordability-concerns

About Market Research Report Store
Since the establishment, Market Research Report Store has determined to take the online market research reports platform to the next level. With our passion and profession, we are designed to be the best among the bests.
Market Research Report Store is one of the most fast-growing and professional online platforms for industry reports, market reports, and professional surveys. Our collection covers more than 100 global markets. We have cooperated with leading publishers and consultant companies to offer the best market intelligence products to our clients with instant access to our database.

Ask a sample and any further questions, please feel free to contact us:
Tel: +00-1-626-3463946 - U.S
Email: [email protected]
Web: http://www.marketresearchreportstore.com/